华夏时报记者杨燕北京报道 在诺和诺德近期公布的一季度业绩中,王牌产品司美格鲁肽在2025年第一季度实现了开门红,三个月约80亿美元的整体销售表现,不仅超过了礼来旗下同类型GLP-1类产品替尔泊肽将近61.5亿美元的销售额,更是一举超过默沙东旗下肿瘤药博利珠单抗(俗称“K药”),登顶全球“药王”宝座。 不过,即使业绩一路向上,诺和诺德在过去半年的股价表现却一路向下,这家在2023年市值一度超过...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.